Ge Long Hui·2025-08-19 10:44Core Insights - The company reported a significant increase in total revenue, rising 74.3% to RMB 730 million for the six months ending June 30, 2025, primarily driven by strong sales of Oubatinib and licensing revenue from Prolium [1] - The loss for the period decreased by 86.7% to RMB 35.6 million, compared to a loss of RMB 268 million for the same period ending June 30, 2024 [1] - The company has a robust cash position of approximately RMB 7.7 billion as of June 30, 2025, allowing for flexible clinical development and investment in competitive product lines [1] Product Development and Milestones - The company achieved significant milestones in product line advancement, including the approval of Oubatinib for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [2] - The combination therapy of Tanshituzumab and Lenalidomide was approved for adult patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplantation (ASCT) [2] - The BCL-2 inhibitor ICP-248 (mesutoclax) entered two registrational clinical studies, and the company's proprietary ADC platform made significant breakthroughs with the first IND submission and clinical trial approval [2] Strategic Partnerships and Market Execution - The company expanded its global footprint through strategic collaborations, including a partnership with Prolium in January 2025 to explore the global potential of a CD3×CD20 bispecific antibody [2] - The commercial execution remains strong, with increased market penetration and substantial revenue growth for Oubatinib, highlighting the company's ability to translate scientific innovation into sustainable business performance [2]